298 related articles for article (PubMed ID: 18640251)
1. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations.
Hiremath PS; Saha RN
Int J Pharm; 2008 Oct; 362(1-2):118-25. PubMed ID: 18640251
[TBL] [Abstract][Full Text] [Related]
2. Controlled release hydrophilic matrix tablet formulations of isoniazid: design and in vitro studies.
Hiremath PS; Saha RN
AAPS PharmSciTech; 2008; 9(4):1171-8. PubMed ID: 19015997
[TBL] [Abstract][Full Text] [Related]
3. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
4. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs.
Prabakaran D; Singh P; Jaganathan KS; Vyas SP
J Control Release; 2004 Mar; 95(2):239-48. PubMed ID: 14980772
[TBL] [Abstract][Full Text] [Related]
5. Alginate microspheres of isoniazid for oral sustained drug delivery.
Rastogi R; Sultana Y; Aqil M; Ali A; Kumar S; Chuttani K; Mishra AK
Int J Pharm; 2007 Apr; 334(1-2):71-7. PubMed ID: 17113732
[TBL] [Abstract][Full Text] [Related]
6. Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone.
Hardy IJ; Windberg-Baarup A; Neri C; Byway PV; Booth SW; Fitzpatrick S
Int J Pharm; 2007 Jun; 337(1-2):246-53. PubMed ID: 17306477
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC.
Shoaib MH; Tazeen J; Merchant HA; Yousuf RI
Pak J Pharm Sci; 2006 Apr; 19(2):119-24. PubMed ID: 16751122
[TBL] [Abstract][Full Text] [Related]
8. Formulation and statistical optimization of a novel crosslinked polymeric anti-tuberculosis drug delivery system.
du Toit LC; Pillay V; Danckwerts MP; Penny C
J Pharm Sci; 2008 Jun; 97(6):2176-207. PubMed ID: 17879985
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Danckwerts MP; Ebrahim S; Pillay V
Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
[TBL] [Abstract][Full Text] [Related]
10. The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules.
Ellard GA
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S343-6; discussion S351-2. PubMed ID: 10593715
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
Panchagnula R; Singh I; Kaur KJ; Kaul CL
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):625-8. PubMed ID: 10669909
[TBL] [Abstract][Full Text] [Related]
12. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
[TBL] [Abstract][Full Text] [Related]
13. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
[TBL] [Abstract][Full Text] [Related]
14. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride.
Bendas ER
Arch Pharm Res; 2009 Sep; 32(9):1317-29. PubMed ID: 19784589
[TBL] [Abstract][Full Text] [Related]
15. Gastric floating matrix tablets: design and optimization using combination of polymers.
Prajapati ST; Patel LD; Patel DM
Acta Pharm; 2008 Jun; 58(2):221-9. PubMed ID: 18515232
[TBL] [Abstract][Full Text] [Related]
16. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
17. Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release.
Hiremath PS; Saha RN
Drug Deliv; 2008; 15(3):159-68. PubMed ID: 18379928
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
19. Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose.
Yi T; Wan J; Xu H; Yang X
Eur J Pharm Sci; 2008 Aug; 34(4-5):274-80. PubMed ID: 18541418
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs.
Bhutani H; Singh S; Jindal KC; Chakraborti AK
J Pharm Biomed Anal; 2005 Oct; 39(5):892-9. PubMed ID: 15978767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
